European Parliament was the setting for the ground-breaking announcement, which was part of an enlightening presentation from Clairvoyant CEO and Co-Founder, Damian Kettlewell. Kettlewell provided industry perspective during an event focused on exploring regulatory pathways for psychedelic therapies in Europe. Clairvoyant
is a clinical biotech company that aims to enable psilocybin therapy in the EU, Canada and the UK for the purpose of treating patients living with Alcohol Use Disorder. Already well into its Phase 2b clinical trials, Clairvoyant anticipates completing its Phase 3 trials from its European headquarters in Portugal.
Already operating in both Canada and Finland, Clairvoyant will join the growing Health Biotech Cluster established by Empowered Startups in concert with Portugal’s government and several of its higher education institutions. Armed with exceptional facilities and research teams, Portugal is quickly becoming an attractive destination for global innovators in search of world class resources and a desirable standard of living. Empowered Startups continues to identify such entrepreneurs as candidates for its HQA Visa program, which facilitates entry into the country as well as providing expert guidance within its business incubator.
More information about the HQA Visa Program can be found at https://hqavisa.pt/ and at https://empoweredstartups.com/portugal-hqa-visa/